| abstract |
In the present invention there is disclosed a compound pharmaceutical preparation for prevention and treatment of arteriosclerosis or xanthoma, whose first agent is selected from a group comprising inhibitors of HMG-Co A reductase, such as pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin and the second agent thereof is selected from a group comprising the following insulin senzibilizing agents: thiazolidinedione compounds, oxazolidinedione compounds or oxathiadiazole compounds, whereby both the agents are present in the form suitable for common or individual administration enabling synergistic activity. |